非侵襲性リキッドバイオプシー市場：タイプ、技術、エンドユーザー別-2025-2030年の世界予測

非侵襲性リキッドバイオプシー市場は、2023年に10億1,000万米ドルと評価され、2024年には11億9,000万米ドルに達すると予測され、CAGR 18.10%で成長し、2030年には32億5,000万米ドルに達すると予測されています。

非侵襲性リキッドバイオプシーは、がんの検出とモニタリングに使用される最先端の診断法で、従来の組織生検に代わる侵襲性の低い代替法を提供します。血液のような体液中の循環腫瘍細胞（CTC）、無細胞DNA（cfDNA）、RNAを分析し、外科的処置を必要とせずに腫瘍の動態に関する重要な洞察を提供します。非侵襲的リキッドバイオプシーの必要性は、サンプリングバイアスや潜在的な外科的合併症といった組織生検の限界に対処し、がんの早期発見、治療効果のモニタリング、再発疾患の検出を促進する能力にあります。その用途は腫瘍学、個別化医療、出生前検査に及び、病院、診断センター、学術機関で使用されています。主な成長要因としては、ゲノミクスとプロテオミクスの進歩、がん罹患率の増加、低侵襲診断技術に対する需要の増加などが挙げられます。さらに、研究開発活動の急増や、がんの早期発見に対する意識の高まりが市場を活性化しています。

しかし、高いコスト、規制の複雑さ、検査の感度と特異性に関する問題などが課題となっています。これらの限界を克服するには、標準化されたプロトコルを開発し、強固な検証試験を通じて臨床的有用性を実証する必要があります。市場関係者は、分子診断技術の革新、検査精度の向上、データ解析のためのAIと機械学習の統合に注力すべきです。バイオファーマ企業、研究機関、ヘルスケアプロバイダー間のパートナーシップとコラボレーションは、専門知識を活用し、市場リーチを拡大するために不可欠です。他の病型への応用拡大、多項目検出の改善、ポイント・オブ・ケア型リキッドバイオプシー装置の開発にも機会が存在します。腫瘍生物学と耐性メカニズムの理解拡大に投資することで、リキッドバイオプシーをがん管理の変革ツールとしてさらに高めることができます。市場はダイナミックで競合情勢にあり、進化する情勢を乗り切り事業の成長を最大化するためには、継続的なイノベーションと戦略的提携が必要です。

市場力学：急速に進化する非侵襲性リキッドバイオプシー市場の主要市場インサイトを公開

非侵襲性リキッドバイオプシー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんの罹患率および有病率の上昇
  • 非侵襲的診断方法への嗜好の高まり
• 市場抑制要因
  • 高度な非侵襲性リキッドバイオプシーに関連する高コスト
• 市場機会
  • 人工知能と非侵襲性リキッドバイオプシーの統合
  • 先進ヘルスケアインフラへの投資の増加
• 市場の課題
  • 異なる技術や腫瘍タイプ間での標準化の欠如

ポーターのファイブフォース：非侵襲性リキッドバイオプシー市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：非侵襲性リキッドバイオプシー市場における外部からの影響の把握

外部マクロ環境要因は、非侵襲性リキッドバイオプシー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析非侵襲性リキッドバイオプシー市場における競合情勢の把握

非侵襲性リキッドバイオプシー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス非侵襲性リキッドバイオプシー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、非侵襲性リキッドバイオプシー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨非侵襲性リキッドバイオプシー市場における成功への道筋を描く

非侵襲性リキッドバイオプシー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんの発生率と罹患率の上昇
    • 非侵襲的診断法への関心が高まる
  • 抑制要因
    • 高度な非侵襲性リキッドバイオプシーに関連する高コスト
  • 機会
    • 人工知能と非侵襲性リキッドバイオプシーの統合
    • 先進的なヘルスケアインフラへの投資増加
  • 課題
    • さまざまな技術や腫瘍の種類にわたる標準化の欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 非侵襲性リキッドバイオプシー市場：タイプ別

• アッセイキット
• 機器
• サービス

第7章 非侵襲性リキッドバイオプシー市場：技術別

• 次世代シーケンシング（NGS）
• RT-PCRとdPCR

第8章 非侵襲性リキッドバイオプシー市場：エンドユーザー別

• 学術研究センター
• 臨床診断検査室
• 病院

第9章 南北アメリカの非侵襲性リキッドバイオプシー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の非侵襲性リキッドバイオプシー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの非侵襲性リキッドバイオプシー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Angle PLC
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Biocept, Inc.
• DiaCarta, Inc.
• Epic Sciences Inc.
• F. Hoffmann-La Roche Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Laboratory Corporation of America Holdings
• Lonza Group Ltd.
• Lucence Diagnostics Pte. Ltd.
• LungLife AI, Inc.
• Mdxhealth BV
• MedGenome Labs Ltd.
• Menarini Silicon Biosystems SpA
• Merck KGaA
• Nonacus Limited
• Norgen Biotek Corporation
• Oasis Diagnostics Corporation
• OraSure Technologies, Inc
• QIAGEN GmbH
• Thermo Fisher Scientific Inc.
• Zymo Research Corp.

LIST OF FIGURES

• FIGURE 1. NON-INVASIVE LIQUID BIOPSY MARKET RESEARCH PROCESS
• FIGURE 2. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NON-INVASIVE LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NON-INVASIVE LIQUID BIOPSY MARKET DYNAMICS
• TABLE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RT-PCR AND DPCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 30. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 117. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

The Non-Invasive Liquid Biopsy Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.19 billion in 2024, and is projected to grow at a CAGR of 18.10%, to USD 3.25 billion by 2030.

Non-invasive liquid biopsy is a cutting-edge diagnostic method used for cancer detection and monitoring, providing a less invasive alternative to traditional tissue biopsies. It involves analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), or RNA in bodily fluids like blood, offering critical insights into tumor dynamics without the need for surgical procedures. The necessity of non-invasive liquid biopsies lies in their ability to facilitate early cancer detection, monitor treatment efficacy, and detect recurrent disease, addressing the limitations of tissue biopsies, such as sampling bias and potential surgical complications. Their applications span across oncology, personalized medicine, and prenatal testing, with usage in hospitals, diagnostic centers, and academic institutions. Key growth factors include advancements in genomics and proteomics, growing cancer prevalence, and increasing demand for minimally invasive diagnostic techniques. Additionally, the surge in research and development activities and growing awareness about early cancer detection are fueling the market.

However, challenges include high costs, regulatory complexities, and issues related to test sensitivity and specificity. Overcoming these limits will entail developing standardized protocols and demonstrating clinical utility through robust validation studies. Market players should focus on innovation in molecular diagnostic technologies, enhancing test accuracy, and integrating AI and machine learning for data analysis. Partnerships and collaborations between biopharma companies, research institutes, and healthcare providers are vital to leverage expertise and expand market reach. Opportunities exist in expanding applications to other disease types, improving multi-analyte detection, and developing point-of-care liquid biopsy devices. Investing in expanding the understanding of tumor biology and resistance mechanisms could further elevate liquid biopsy as a transformative tool in cancer management. The market is dynamic and competitive, requiring continuous innovation and strategic collaborations to navigate the evolving landscape and maximize business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-Invasive Liquid Biopsy Market

The Non-Invasive Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence and prevalence of cancer
  • Increasing preference for noninvasive diagnostic procedures
• Market Restraints
  • High cost associated with advanced non-invasive liquid biopsy
• Market Opportunities
  • Integration of artificial intelligence with non-invasive liquid biopsy
  • Increasing investment for advanced healthcare infrastructure
• Market Challenges
  • Lack of standardization across different techniques and tumor types

Porter's Five Forces: A Strategic Tool for Navigating the Non-Invasive Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-Invasive Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-Invasive Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-Invasive Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-Invasive Liquid Biopsy Market

A detailed market share analysis in the Non-Invasive Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-Invasive Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-Invasive Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-Invasive Liquid Biopsy Market

A strategic analysis of the Non-Invasive Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-Invasive Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Angle PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocept, Inc., DiaCarta, Inc., Epic Sciences Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Lucence Diagnostics Pte. Ltd., LungLife AI, Inc., Mdxhealth BV, MedGenome Labs Ltd., Menarini Silicon Biosystems SpA, Merck KGaA, Nonacus Limited, Norgen Biotek Corporation, Oasis Diagnostics Corporation, OraSure Technologies, Inc, QIAGEN GmbH, Thermo Fisher Scientific Inc., and Zymo Research Corp..

Market Segmentation & Coverage

This research report categorizes the Non-Invasive Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Assay Kits, Instruments, and Services.
• Based on Technology, market is studied across Next Generation Sequencing (NGS) and RT-PCR and dPCR.
• Based on End-user, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, and Hospital.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence and prevalence of cancer
    • 5.1.1.2. Increasing preference for noninvasive diagnostic procedures
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with advanced non-invasive liquid biopsy
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of artificial intelligence with non-invasive liquid biopsy
    • 5.1.3.2. Increasing investment for advanced healthcare infrastructure
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of standardization across different techniques and tumor types
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Non-Invasive Liquid Biopsy Market, by Type

• 6.1. Introduction
• 6.2. Assay Kits
• 6.3. Instruments
• 6.4. Services

7. Non-Invasive Liquid Biopsy Market, by Technology

• 7.1. Introduction
• 7.2. Next Generation Sequencing (NGS)
• 7.3. RT-PCR and dPCR

8. Non-Invasive Liquid Biopsy Market, by End-user

• 8.1. Introduction
• 8.2. Academic & Research Centers
• 8.3. Clinical Diagnostic Laboratories
• 8.4. Hospital

9. Americas Non-Invasive Liquid Biopsy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Non-Invasive Liquid Biopsy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Non-Invasive Liquid Biopsy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Angle PLC
• 2. Bio-Rad Laboratories, Inc.
• 3. Bio-Techne Corporation
• 4. Biocept, Inc.
• 5. DiaCarta, Inc.
• 6. Epic Sciences Inc.
• 7. F. Hoffmann-La Roche Ltd.
• 8. Guardant Health, Inc.
• 9. Illumina, Inc.
• 10. Integrated DNA Technologies, Inc.
• 11. Laboratory Corporation of America Holdings
• 12. Lonza Group Ltd.
• 13. Lucence Diagnostics Pte. Ltd.
• 14. LungLife AI, Inc.
• 15. Mdxhealth BV
• 16. MedGenome Labs Ltd.
• 17. Menarini Silicon Biosystems SpA
• 18. Merck KGaA
• 19. Nonacus Limited
• 20. Norgen Biotek Corporation
• 21. Oasis Diagnostics Corporation
• 22. OraSure Technologies, Inc
• 23. QIAGEN GmbH
• 24. Thermo Fisher Scientific Inc.
• 25. Zymo Research Corp.